Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
J Clin OncolJul 14, 2026 (epub)
Marco Ladetto, Katja Gutmair, Rita Tavarozzi et al.
✦ AI-curated · Sources linked
In 30 seconds
The TRIANGLE trial evaluated the impact of rituximab maintenance (RM) on progression-free survival (PFS) and overall survival (OS) in younger, untreated patients with mantle cell lymphoma (MCL) receiving ibrutinib-containing therapy. This randomized controlled trial found that RM significantly improved PFS, with a 4-year PFS probability of 85% vs 73% in the ibrutinib group and 90% vs 75% in the ASCT group.
Key findings
- RM improved PFS in the ibrutinib group (4-year PFS: 85% vs 73%).
- In the ASCT group, RM also improved PFS (4-year PFS: 90% vs 75%).
- RM groups had a higher risk of grade 3 to 5 infectious toxicity (I: 34% vs 11%; A + I: 41% vs 18%).
- Trends toward prolonged OS were observed in RM groups.
Why it matters
The findings suggest that incorporating rituximab maintenance into ibrutinib-containing regimens may enhance remission duration in younger patients with MCL, potentially influencing treatment strategies in this population.